Glaxosmithkline Pharmaceuticals Ltd share price gained 1.68% to Rs 2653.45. The Company's net profit contracted by 14.64% to Rs 237.18 crore, while revenue from operations softened by 5.71% to Rs 938.44 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.2 lakh crore, easing 5.88%. It has inched up 1.27% over last one week and climbed by 13.99% in last one month while the market capitalization of Glaxosmithkline Pharmaceuticals Ltd has marginally improved by 4.05% and 12.33% in the same period respectively. Profit before tax (PBT) of Glaxosmithkline Pharmaceuticals Ltd stood at Rs 322.45 crore in Q2 FY26, surging by 15.58% year-on-year, and dropping 13.58% quarter-on-quarter. EBITDA came in at Rs 252 crore, jumping 21.33% YoY and crashing by 20.08% sequentially. Total expenses posted a minor rise of 0.19% to Rs 658.78 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 72.95 crore, registering a fall of 35.48% YoY, while employee benefits expense was at Rs 159.04 crore, slipping by 3.47% YoY. For the TTM ended FY26, revenue from operations inched higher 1.93% to Rs 3821.67 crore, while net profit expanded by 11.69% to Rs 1035.98 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 103008% to Rs 1163.84 crore, and PBT registered a growth of 11.60% to Rs 1406.01 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 903.3 crore in FY26, as against Rs 1289.91 crore in FY25. Glaxosmithkline Pharmaceuticals Ltd plunged by 15.98% in last one year, underperforming the benchmark BSE Sensex which has eased by 3.81% during the same period.
